nach oben

Erschienen in:

30.10.2013 | Fortbildung

Physiologische Veränderungen erschweren die Behandlung

Altersepilepsien – Teil II: Therapie

verfasst von: Prof. Dr. med. Hermann Stefan

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei der Therapie der Altersepilepsie bergen allgemeine altersbezogene Leiden, Multimorbidität, niedriges Körpergewicht sowie eingeschränkte Leber- und Nierenfunktion Risiken für Medikamentennebenwirkungen. Optimierte Versorgungssysteme mit neurogeriatrischer Fachkompetenz und Complianceprogramme können die Situation der Altersepilepsie aber deutlich verbessern.

Cloyd J. Commonly used antiepileptic drugs: age-related pharmacokinetics. In Rowan AJ., Ramsey RE., eds. Seizures and epilepsy in the elderly. Boston: Butterworth-Heinemann, 1997;219–228.

Müller WE. Besonderheiten der Psychopharmakotherapie im Alter, In: Förstel H. (Ed). Lehrbuch der Gerontopsychiatrie, Enke, Stuttgart 1997;pp:141–151.

Nolan L K, O’Malley O. Prescribing for the elderly. Part I: Sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc. 1988;36:142–149.PubMed

Ciorciaro C, Hartmann K, Kuhn M. Unterscheiden sich die relativen Häufigkeiten unerwünschter Arzneimittelreaktionen in Abhängigkeit vom Alter? Eine Auswertung des spontanen Meldesystems der SANZ. Schweiz. Med Wochenschr 1998;128:254–258.

Ramsay RE, Rowan AJ, Slater JD, Collins J, Nemire R, Oritz WR and the VA Cooperativ Study Group: Effect of age on epilepsy and its treatment: results form the VA Co-operative study (abstract). Epilepsia 1994;35:91.CrossRef

Cockerell OC, Johnson, AL, Sander AS, et al. Prognosis of epilepsy: a review and further analysis of the first nine years of the british National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997;38:31–46.PubMedCrossRef

Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, Phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N. Engl. J. Med. 1985;313:145–151.PubMedCrossRef

Mattson RH, Cramer JA, Collins JF and the Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group: A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized seizures in adults. N. Engl. J. Med. 1992;327:765–771.PubMedCrossRef

Cameron H, MacPhee GJA. Anticonvulsant therapy in the elderly — a need for placebo controlled trials. Epilepsy Res. 1995;21:149–157.PubMedCrossRef

10.

Pederson B, Anderson G. Treatment of epilepsy in old age: In: Chadwick, D. (ed.): Fourth International Symposium on sodium Valproate and Epilepsy. International Congress and Symposium Series Number 152: Royal Society of Medicine Services. London 1989;p:130–132.

11.

Tallis R. Preventing drug reactions in the elderly: can we do better? J R Soc Med 1994;23:14–15.

12.

Perucca E, Aldenkamp A, Tallis R, et al. Role of valproate across the ages. Treatment of epilepsy in the elderly. Acta Neurol Scand 2006;114;28–37.CrossRef

13.

Giorgi L, Gomez G, O’Neill F, et al. The tolerability of lamotrigine in elderly patients with epilepsy. Drugs Aging 2001;18:621–630.PubMedCrossRef

14.

Rowan AJ. Epilepsy in older adults. Common morbidities influence development, treatment strategies, and expected outcomes. Geriatrics 2005;60:30–32.PubMed

15.

Glauser T, Ben-Menachem E, Bourgeois B et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094–1120.PubMedCrossRef

16.

Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64:1868–1873.PubMedCrossRef

17.

Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine in patients with poststroke seizure. Clin Neuropharmacol 2007;30:189–195.

18.

Saetre E, Perucca E, Isojarvi J, Gjerstad L. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007;48:1292–302PubMedCrossRef

19.

Karceski S, Morell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion. Epilepsy Behav 2005;7:1–64.CrossRef

20.

Krämer G, May T, Schmitz B, et al. Epilepsiebehandlung bei Erwachsenen 2007: Ergebnisse einer Expertenbefragung in Deutschland, Österreich und der Schweiz. Akt Neurol 2007;34:121.

21.

Mattson R, Kamin M, SIVC. Seizure freedom with topiramate: Results from an open follow on to a double blind titration study. Epilepsia 1998;39:55.

22.

Stefan H, Hubbertz L, Peglan J, et al. Epilepsy outcomes in elderly treated with topiramate. Acta Neurol Scand 2008;118:169–174.CrossRef

23.

Morrell MJ, Leppik I, Frechn J, et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 2003;54:153–161.PubMedCrossRef

24.

Werhahn KJ. Epileptische Anfälle im Alter. Der Nervenarzt 2009:83(2):201–204.CrossRef

25.

Elger C, Bialer M, Cramer JA et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007;48:497–504.PubMedCrossRef

26.

Pugh MJ, Van Cott AC, Cramer JA, et al. Trends in antiepileptic drug prescribing for older patients with new-onset epilepsy: 2000-2004. Neurology 2008;70:2171–2178.PubMedCrossRef

27.

Cordonnier C, Henon H, Derambure P, et al. Early epileptic seizures after stroke are associated with increased risk of new-onset dementia. J Neurol Neurosurg Psychiatry 2007;78: 514–516.PubMedCrossRef

28.

Cleary P, Shorvon S, Tallis R. Late-onset seizures as a predictor of subsequent stroke. The Lancet 2004; 363:1184–1186CrossRef

29.

Kwan J, Guenther A. Antiepileptic drugs for the primary and secondary prevention of seizures after intracranial venous thrombosis. Cochrane Database Syst Rev 2006;3:CD005501.PubMed

30.

Adams HP, Jr., del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655–1711.PubMedCrossRef

31.

Ferro JM, Pinto F. Poststroke epilepsy: epidemiology, pathophysiology and management. Drugs Aging 2004;21:639–653.PubMedCrossRef

32.

Ryvlin P, Montavont A, Nighoghossian N. Optimizing therapy of seizures in stroke patients. Neurology 2006;67:3–9.CrossRef

33.

Myint PK, Staufenberg EF, Sabanathan K. Post-stroke seizure and post-stroke epilepsy. Postgrad Med J 2006;82:568–72.PubMedCrossRef

34.

Ringleb P, Schellinger PD, Hacke W. Leitlinien zum Management von Patienten mit akutem Hirninfarkt oder TIA der Europäischen Schlaganfallorganisation 2008. Nervenarzt 2008;79:936–957.PubMedCrossRef

35.

Grivas A, Schramm J, Kral T, et al. Surgical treatment for refractory temporal lobe epilepsy in the elderly: seizure outcome and neuropsychological sequels compared with a younger cohort. Epilepsia 2006;47(8):1364–1372.PubMedCrossRef

36.

Acosta I, Vale F, atum WO 4th, et al. Epilepsy surgery after age 60. Epilepsy Behav 2008;12(2):324–325.PubMedCrossRef

37.

Bachmann K. Coronal heart disease. In D. Blatt, Altersmedizin, Schattauer-Verlag, Stuttgart, New York, 1997; p:59–71.

38.

Hüll M, Bauer J. Alzheimer disease and vascular dementia. In: D. Blatt, Altersmedizin. Schattauer-Verlag, Stuttgart, New York 1997;p:520–554.

39.

Schmidt D, Seldon L. Adverse effects of antiepileptic drugs. Raven Press, New York 1982

40.

Bartl R. Antiepileptic drug-induced osteopathy. Subtypes, pathogenesis, prevention, early diagnosis and treatment. Dtsch Med Wochenschr 2007;132:1475–1479.PubMedCrossRef

41.

Rowe DJ. Disturbane of calcium metabolism by anticonvulsant drugs. Brit med. J 1970;4:73–76.PubMedCrossRef

42.

Pack AM, Olarte LS, Morrell MJ et al. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 2003; 4(2):169–174.PubMedCrossRef

43.

Pack AM, Morrell MJ, Marcus R et al. Bone mass and turnover in women with epilepsy on antiepileptic drugs monotherapy. Ann Neurol. 2005;57:252–257.PubMedCrossRef

44.

Briggs DE, French JA. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf 2004;3:415–424.PubMedCrossRef

45.

Sheth RD. Effect of carbamazepine and valproate on bone mineral density. J Pediatric 1995;127:256–262.CrossRef

46.

Nissen-Meyer LS, Svalheim S, Taubøll E et al. How can antiepileptic drugs affect bone mass, structure and metabolism? Lessons from animal students. Seizure 2008;17:187–191.PubMedCrossRef

47.

Pack AM. The association between antiepileptic drugs and bone disease. Epilepsy Curr 2003;3:91–95.PubMedCrossRef

48.

Vestergaard P. Changes in bone turnover, bone mineral and fracture risk induced by drugs used to treat epilepsy. Curr Drug Saf 2008:168–172.

49.

Nissen-Meyers LS, Svalheim S, Taubøll E et al. Levetiracetam, phenytoin,, and valproate act differently on rat bone mass, structure and metabolism. Epilepsia 2007;48:1850–1860.CrossRef

50.

Coppola G, Fortunato D, Auricchio G et al. Bon emineral density in children, adolsescents, and young adults with epilepsy. Epilepsia 2009;50:2140–2146.PubMedCrossRef

51.

Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004;45:1330–1337.PubMedCrossRef

52.

Sheth RD, Hermann BP. Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatric Neurology 2007;37:250–254.PubMedCrossRef

53.

Ensrud KE, Walczak TS, Blackwell TL et al. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008;71:723–730.PubMedCrossRef

54.

Garrard J, Cloyd J, Gross C, et al.. Factors associated with antiepileptic drug use among elderly nursing home residents. J Gereontol A Biol Sci Med Sci 2000;55:384–392.CrossRef

55.

Hanlon JT, Schmader KE, Koronkowski MJ et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1998;46:252–253.

56.

Cooper JW. Probable adverse drug reaction in a rural geriatric nursing home population: A four-years study. JAGS 1996;44:194–197.

57.

Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003;289:1107–1116.PubMedCrossRef

58.

Haupt M. Depressive Störungen im Alter — Kofaktoren, Kosyndrome und Komorbidität. NeuroGeriatrie 2004;1:25–31.

59.

Fife TD, Blum D, Fisher RS. Measuring the effect of antiepileptic medications on balance in older people. EpilepsyRes 2006;70:103–109.CrossRef

60.

Flierl-Hecht A, Pfäfflin M, May TW, et al. Werden Epilepsien bei älteren Menschen übersehen? Eine Untersuchung in Altersheimen. Nervenarzt 2003;74:691–698.PubMedCrossRef

Titel: Physiologische Veränderungen erschweren die Behandlung
Altersepilepsien – Teil II: Therapie
verfasst von: Prof. Dr. med. Hermann Stefan
Publikationsdatum: 30.10.2013
Verlag: Urban & Vogel
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 11/2013
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-013-0426-x

Neu in den Fachgebieten Neurologie und Psychiatrie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Physiologische Veränderungen erschweren die Behandlung

Altersepilepsien – Teil II: Therapie

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2013

Stressforschung: Mit Achtsamkeit andere Wege suchen

Resveratrol-Studie: Polyphenol bessert das Gedächtnis im Alter

Agitation bei Alzheimer-Demenz: Risperidon nicht zu früh absetzen

Named-Patient-Zugangsprogramm für Epilepsiepatienten

Neue Studien zur Demenz

Im Praxisbetrieb gesichert online gehen

Neu in den Fachgebieten Neurologie und Psychiatrie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Delir kann Demenz begünstigen

Manche Gestagene können das Risiko für Meningeome erhöhen